Interní Med. 2006; 8(7): 327-329

New antitrombotic drugs

MUDr. Jan Novotný Ph.D

Centrum pro trombózu a hemostázu, oddělení klinické hematologie, FN Brno

The hypercoagulable states belong among the most frequent causes of morbidity and mortality in the developed countries worldwide. The hemostasis plays an important role not only in stopping of bleeding, but takes part also in immunity, wound healing, and in the processes of growing, progression, and metastasing of malignant tumors. This is the cause why many research teams pay great attention to the problematics of hemostasis, including the development of new antithrombotic drugs. The hemostasis is being explored in details on many levels, creating so the basis of developing and testing of new drugs in both the preclinical and clinical trials. The most promising drugs at present represent the pentasaccharides, the direct inhibitors of factor Xa, and the direct inhibitors of thrombin. It may be expected, that these new antithrombotics replace the classic drugs (heparins and vitamin K antagonists) in the prevention and treatment of thrombosis in both the venous and arterial circulation. The main disadvantage of new antithrombotics is absence of specific antidotes, but the bleeding complications seem to be less frequent than in therapy with classical antithrombotics. The universal antihemorrhagic drug against serious bleeding after these drugs might be the recombinant factor VIIa.

Keywords: Key words: the hypercoagulable states, new antithrombotics, fondaparinux, idraparinux, ximelagatran, dabigatran.

Published: June 1, 2006  Show citation